216
Views
38
CrossRef citations to date
0
Altmetric
Original Article

Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine

, &
Pages 821-829 | Published online: 12 Oct 2003

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Huijing Tan, Lijie Zuo, Shutao Ma, Dingyuan Wang, Rui Li, Yiqi Yang, Weili Liu & Yihebali Chi. (2021) Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma. Cancer Management and Research 13, pages 9075-9083.
Read now
Cong Luo, Jiayu Shen, Jieer Ying, Xianhua Fang, Xiaohong Wang, Zhixuan Fu & Peng Liu. (2017) Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy. OncoTargets and Therapy 10, pages 4553-4557.
Read now

Articles from other publishers (36)

Myrna Eliann Reinhardt, Tiffany Sun, Catherina X. Pan, Chrysalyne D. Schmults, Erica H. Lee & Abigail B. Waldman. (2022) A systematic review of patient-reported outcome measures for advanced skin cancer patients. Archives of Dermatological Research 315:6, pages 1473-1480.
Crossref
P. Bernard, J. Savard, K. Steindorf, M.G. Sweegers, K.S. Courneya, R.U. Newton, N.K. Aaronson, P.B. Jacobsen, A.M. May, D.A. Galvao, M.J. Chinapaw, M.M. Stuiver, K.A. Griffith, I. Mesters, H. Knoop, M.M. Goedendorp, M. Bohus, L. Thorsen, M.E. Schmidt, C.M. Ulrich, G.S. Sonke, W. van Harten, K.M. Winters-Stone, M.J. Velthuis, D.R. Taaffe, W. van Mechelen, M.J. Kersten, F. Nollet, J. Wenzel, J. Wiskemann, I.M. Verdonck-de Leeuw, J. Brug & L.M. Buffart. (2019) Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses. Journal of Psychosomatic Research 124, pages 109746.
Crossref
P.V. Chernyshov, A. Lallas, L. Tomas‐Aragones, M. Arenbergerova, M. Samimi, L. Manolache, A. Svensson, S.E. Marron, F. Sampogna, S. Spillekom‐vanKoulil, A. Bewley, A.M. Forsea, G.B. Jemec, J.C. Szepietowski, M. Augustin & A.Y. Finlay. (2019) Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer. Journal of the European Academy of Dermatology and Venereology 33:5, pages 816-827.
Crossref
Winson Y. Cheung, Michelle K. White, Martha S. Bayliss, Angela Stroupe, Andrew Lovley, Bellinda L. King-Kallimanis & Kathryn Lasch. (2018) Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. Supportive Care in Cancer 27:1, pages 219-227.
Crossref
Bruno Kovic, Xuejing Jin, Sean Alexander Kennedy, Mathieu Hylands, Michal Pedziwiatr, Akira Kuriyama, Huda Gomaa, Yung Lee, Morihiro Katsura, Masafumi Tada, Brian Y. Hong, Sung Min Cho, Patrick Jiho Hong, Ashley M. Yu, Yasmin Sivji, Augustin Toma, Li Xie, Ludwig Tsoi, Marcin Waligora, Manya Prasad, Neera Bhatnagar, Lehana Thabane, Michael Brundage, Gordon Guyatt & Feng Xie. (2018) Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology. JAMA Internal Medicine 178:12, pages 1586.
Crossref
Winson Y. Cheung, Martha S. Bayliss, Michelle K. White, Angela Stroupe, Andrew Lovley, Bellinda L. King-Kallimanis & Kathryn Lasch. (2018) Humanistic burden of disease for patients with advanced melanoma in Canada. Supportive Care in Cancer 26:6, pages 1985-1991.
Crossref
Sandro Pasquali, Andreas V Hadjinicolaou, Vanna Chiarion Sileni, Carlo Riccardo Rossi & Simone Mocellin. (2018) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews 2020:11.
Crossref
Teresa M. Petrella, Caroline Robert, Erika Richtig, Wilson H. MillerJr.Jr., Giuseppe V. Masucci, Euan Walpole, Celeste Lebbe, Neil Steven, Mark R. Middleton, Darcy Hille, Wei Zhou, Nageatte Ibrahim & Jonathan Cebon. (2017) Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. European Journal of Cancer 86, pages 115-124.
Crossref
Jeff Dunn, Maggie Watson, Joanne F. Aitken & Melissa K. Hyde. (2017) Systematic review of psychosocial outcomes for patients with advanced melanoma. Psycho-Oncology 26:11, pages 1722-1731.
Crossref
Thomas K. Eigentler, Corinna Mühlenbein, Markus Follmann, Dirk Schadendorf & Claus Garbe. (2017) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 15:6, pages e1-e41.
Crossref
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Caroline Robert, Omid Hamid, Adil Daud, Alfons van den Eertwegh, Lee Cranmer, Steven O'Day, Igor Puzanov, Jacob Schachter, Christian Blank, April Salama, Carmen Loquai, Janice M. Mehnert, Darcy Hille, Scot Ebbinghaus, S. Peter Kang, Wei Zhou & Antoni Ribas. (2016) Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer 67, pages 46-54.
Crossref
Janine Zimmer, Dorothee Niemann, Kirsten Seltmann, Lars Fischer, Holger Christiansen, Roberto Frontini, Wieland Kiess, Martina P Neininger, Astrid Bertsche & Thilo Bertsche. (2016) Managing of oral medicines in paediatric oncology: can a handbook and a pharmaceutical counselling intervention for patients and their parents prevent knowledge deficits? A pilot study. European Journal of Hospital Pharmacy 23:2, pages 100-105.
Crossref
John F. Thompson, Sanjiv S. Agarwala, B. Mark Smithers, Merrick I. Ross, Charles R. Scoggins, Brendon J. Coventry, Susan J. Neuhaus, David R. Minor, Jamie M. Singer & Eric A. Wachter. (2014) Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Annals of Surgical Oncology 22:7, pages 2135-2142.
Crossref
J.-J. Grob, M.M. Amonkar, S. Martin-Algarra, L.V. Demidov, V. Goodman, K. Grotzinger, P. Haney, E. Kämpgen, B. Karaszewska, C. Mauch, W.H. MillerJrJr, M. Millward, B. Mirakhur, P. Rutkowski, V. Chiarion-Sileni, S. Swann & A. Hauschild. (2014) Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology 25:7, pages 1428-1436.
Crossref
Katrin Ruth Sigurdardottir, Line Oldervoll, Marianne Jensen Hjermstad, Stein Kaasa, Anne Kari Knudsen, Erik Torbjørn Løhre, Jon Håvard Loge & Dagny Faksvåg Haugen. (2014) How Are Palliative Care Cancer Populations Characterized in Randomized Controlled Trials? A Literature Review. Journal of Pain and Symptom Management 47:5, pages 906-914.e17.
Crossref
Lynne I. Wagner & David Cella. 2013. Dermatologic Principles and Practice in Oncology. Dermatologic Principles and Practice in Oncology 60 68 .
Gabriele Schubert-Fritschle, Anne Schlesinger-Raab, Rüdiger Hein, Wilhelm Stolz, Matthias Volkenandt, Dieter Hölzel & Jutta Engel. (2013) Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study. International Journal of Dermatology 52:6, pages 693-704.
Crossref
Annette Pflugfelder, Corinna Kochs, Andreas Blum, Marcus Capellaro, Christina Czeschik, Therese Dettenborn, Dorothee Dill, Edgar Dippel, Thomas Eigentler, Petra Feyer, Markus Follmann, Bernhard Frerich, Maria-Katharina Ganten, Jan Gärtner, Ralf Gutzmer, Jessica Hassel, Axel Hauschild, Peter Hohenberger, Jutta Hübner, Martin Kaatz, Ulrich R. Kleeberg, Oliver Kölbl, Rolf-Dieter Kortmann, Albrecht Krause-Bergmann, Peter Kurschat, Ulrike Leiter, Hartmut Link, Carmen Loquai, Christoph Löser, Andreas Mackensen, Friedegund Meier, Peter Mohr, Matthias Möhrle, Dorothee Nashan, Sven Reske, Christian Rose, Christian Sander, Imke Satzger, Meinhard Schiller, Heinz-Peter Schlemmer, Gerhard Strittmatter, Cord Sunderkötter, Lothar Swoboda, Uwe Trefzer, Raymond Voltz, Dirk Vordermark, Michael Weichenthal, Andreas Werner, Simone Wesselmann, Ansgar J. Weyergraf, Wolfgang Wick, Claus Garbe & Dirk Schadendorf. (2013) S3-Guideline “Diagnosis, therapy and follow-up of melanoma” - short version. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 11:6, pages 563-602.
Crossref
Dirk Schadendorf, Corinna Kochs & Elisabeth LivingstoneDirk Schadendorf, Corinna Kochs & Elisabeth Livingstone. 2013. Handbook of Cutaneous Melanoma. Handbook of Cutaneous Melanoma 79 104 .
Khurum H Khan, Rebecca B Goody, Hassan Hameed, Awais Jalil, Vicky M Coyle & James JA McAleer. (2018) Metastatic Melanoma: A Regional Review and Future Directions. Tumori Journal 98:5, pages 575-580.
Crossref
Janice N. Cormier, Kate D. Cromwell & Merrick I. Ross. (2012) Health-Related Quality of Life in Patients with Melanoma: Overview of Instruments and Outcomes. Dermatologic Clinics 30:2, pages 245-254.
Crossref
Dennis A Revicki, Alfons JM van den Eertwegh, Paul Lorigan, Celeste Lebbe, Gerald Linette, Christian H Ottensmeier, Shima Safikhani, Marianne Messina, Axel Hoos, Samuel Wagner & Srividya Kotapati. (2012) Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes 10:1, pages 66.
Crossref
Lucio Tentori, Annalisa Susanna Dorio, Emanuela Mazzon, Alessia Muzi, Andrea Sau, Salvatore Cuzzocrea, Patrizia Vernole, Giorgio Federici, Anna Maria Caccuri & Grazia Graziani. (2011) The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. European Journal of Cancer 47:8, pages 1219-1230.
Crossref
Mariana Tremel Barbato, Lucio Bakos, Renato Marchiori Bakos, Rita Prieb & Cláudia Dickel de Andrade. (2011) Preditores de qualidade de vida em pacientes com melanoma cutâneo no serviço de dermatologia do Hospital de Clínicas de Porto Alegre. Anais Brasileiros de Dermatologia 86:2, pages 249-256.
Crossref
A. Schlesinger-Raab, G. Schubert-Fritschle, R. Hein, W. Stolz, M. Volkenandt, D. Hölzel & J. Engel. (2010) Quality of life in localised malignant melanoma. Annals of Oncology 21:12, pages 2428-2435.
Crossref
K M Beusterien, S M Szabo, S Kotapati, J Mukherjee, A Hoos, P Hersey, M R Middleton & A R Levy. (2009) Societal preference values for advanced melanoma health states in the United Kingdom and Australia. British Journal of Cancer 101:3, pages 387-389.
Crossref
Steve Nicholson. 2009. Skin Cancer after Organ Transplantation. Skin Cancer after Organ Transplantation 467 481 .
Wen-Jen Hwu, Ana E. Ayala & Ingrid M. Hernandez. (2008) Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. Oncology Reviews 2:3, pages 183-193.
Crossref
Richard P. Cashin, Philip Lui, M?rcio Machado, Michiel E.H. Hemels, Patricia K. Corey-Lisle & Thomas R. Einarson. (2008) Advanced Cutaneous Malignant Melanoma: A Systematic Review of Economic and Quality-of-Life Studies. Value in Health 11:2, pages 259-271.
Crossref
Michael F. Back. 2008. Radiation Oncology. Radiation Oncology 513 527 .
Hussein A. Tawbi & John M. Kirkwood. (2007) Management of Metastatic Melanoma. Seminars in Oncology 34:6, pages 532-545.
Crossref
Ian Quirt, Shailendra Verma, Teresa Petrella, Kate Bak & Manya Charette. (2007) Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review. The Oncologist 12:9, pages 1114-1123.
Crossref
Ann M. Berger, Jayashri Sankaranarayanan & Shinobu Watanabe‐Galloway. (2007) Current methodological approaches to the study of sleep disturbances and quality of life in adults with cancer: a systematic review. Psycho-Oncology 16:5, pages 401-420.
Crossref
Roland KaufmannKonstanze SpiethUlrike LeiterCornelia MauchPeter von den DrieschThomas VogtRuthild LinseWolfgang TilgenDirk SchadendorfJürgen C. BeckerGünther SebastianSven KrengelLutz KretschmerClaus GarbeReinhard Dummer. (2005) Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology 23:35, pages 9001-9007.
Crossref
M Clemons, J Kelly, A J Watson, A Howell, R S McElhinney, T B H McMurry & G P Margison. (2005) O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. British Journal of Cancer 93:10, pages 1152-1156.
Crossref
Jaime Feliu Batlle, Enrique Espinosa Arranz, Javier de Castro Carpeño, Enrique Casado Sáez, Pilar Zamora Auñón, Andrés Redondo Sánchez & Manuel González Barón. (2004) Oral chemotherapy: potential benefits and limitationsQuimioterapia oral: beneficios y limitaciones potenciales. Clinical and Translational Oncology 6:6, pages 335-340.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.